According to the authors, such molecular signature accounts for the “shared clinical features, resistance to AR inhibition and chemotherapy sensitivity and should serve as the foundation for a biologically-defined therapeutically relevant classification of prostate cancer” [35]. This evidence concerns the gene AR and prostate carcinoma.